After adjusting for baseline HDL subclass distribution , body mass index , LDL-C and the ratio triglycerides/HDL-C , there was a significant increase in large HDL by about 3.9 percentage points ( P < 0.05 ) and a decrease in intermediate HDL by about 3.5 percentage points ( P < 0.01 ) in both simvastatin-containing treatment arms in comparison to ezetimibe .